COVID-19 Information

Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program - The patient was treated with PLX cell therapy at Holy Name Medical Center in New Jersey, an acute care facility that is currently an active site for Pluristem’s Phase III critical limb ischemia (CLI) study. Prior to treatment with PLX, the patient was critically ill with respiratory failure due to acute respiratory distress syndrome (ARDS) and was under mechanical ventilation in an intensive care unit (ICU) for three weeks.

  • All treated patients were in Intensive Care Units (ICU) on ventilators and suffered from Acute Respiratory Distress Syndrome (ARDS)
  • 100% survival rate for all seven patients
  • 6 patients completed 1 week follow up; the seventh patient was treated on April 5 2020
  • 4 of the 6 (66%) patients that completed 1 week follow up demonstrated improvement in respiratory parameters
  • 3 of the 6 (50%) patients that completed 1 week follow up are in advanced stages of weaning from ventilators
  • Pluristem plans to apply for initiation of multinational clinical trial for treatment of complications associated with COVID-19

For more information: https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-COVID-19-First-Patient-in-US-FINAL-FOR-RE…;https://www.pluristem.com/wp-content/uploads/2020/04/PSTI-PR-Follow-up-on-Covid-19-treatments-FINAL-FOR-RELEASE.pdf 

See also: Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Stage
Expanded Access
Company Type
Late Onset Intervention